CA2499738A1 - Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes - Google Patents
Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes Download PDFInfo
- Publication number
- CA2499738A1 CA2499738A1 CA002499738A CA2499738A CA2499738A1 CA 2499738 A1 CA2499738 A1 CA 2499738A1 CA 002499738 A CA002499738 A CA 002499738A CA 2499738 A CA2499738 A CA 2499738A CA 2499738 A1 CA2499738 A1 CA 2499738A1
- Authority
- CA
- Canada
- Prior art keywords
- pyridylmethyl
- combination
- vitamin
- myelodysplastic syndromes
- warm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41317602P | 2002-09-24 | 2002-09-24 | |
| US60/413,176 | 2002-09-24 | ||
| PCT/EP2003/010578 WO2004028542A1 (en) | 2002-09-24 | 2003-09-23 | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2499738A1 true CA2499738A1 (en) | 2004-04-08 |
Family
ID=32043216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002499738A Abandoned CA2499738A1 (en) | 2002-09-24 | 2003-09-23 | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20060128716A1 (enExample) |
| EP (1) | EP1545534B1 (enExample) |
| JP (1) | JP2006502195A (enExample) |
| KR (1) | KR20050074450A (enExample) |
| CN (1) | CN100372535C (enExample) |
| AT (1) | ATE359789T1 (enExample) |
| AU (1) | AU2003299065B2 (enExample) |
| BR (1) | BR0314647A (enExample) |
| CA (1) | CA2499738A1 (enExample) |
| CR (1) | CR7754A (enExample) |
| DE (1) | DE60313344T2 (enExample) |
| EC (1) | ECSP055700A (enExample) |
| ES (1) | ES2285251T3 (enExample) |
| HR (1) | HRP20050281A2 (enExample) |
| MX (1) | MXPA05003161A (enExample) |
| NO (1) | NO20051936L (enExample) |
| PL (1) | PL374696A1 (enExample) |
| PT (1) | PT1545534E (enExample) |
| RS (1) | RS20050228A (enExample) |
| RU (1) | RU2353364C2 (enExample) |
| WO (1) | WO2004028542A1 (enExample) |
| ZA (1) | ZA200502212B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE407683T1 (de) * | 1997-10-15 | 2008-09-15 | Polarx Biopharmaceuticals Inc | Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von multiplen myelom |
| WO2007030582A2 (en) | 2005-09-09 | 2007-03-15 | Bristol-Myers Squibb Company | Acyclic ikur inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132458B2 (en) * | 1994-08-10 | 2006-11-07 | Chemaphor Inc. | Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
| IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| RU2136308C1 (ru) * | 1994-11-16 | 1999-09-10 | Жемчугов Владислав Евгеньевич | Стимулятор роста костно-мозговых клеток человека |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CA2366857C (en) * | 1999-03-30 | 2010-12-14 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
| AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
| CA2393252A1 (en) * | 1999-12-06 | 2001-06-07 | Paul Calabresi | Use of methylol-containing compounds to treat tumors |
-
2003
- 2003-09-23 CA CA002499738A patent/CA2499738A1/en not_active Abandoned
- 2003-09-23 AU AU2003299065A patent/AU2003299065B2/en not_active Ceased
- 2003-09-23 RU RU2005112711/14A patent/RU2353364C2/ru not_active IP Right Cessation
- 2003-09-23 RS YUP-2005/0228A patent/RS20050228A/sr unknown
- 2003-09-23 PL PL03374696A patent/PL374696A1/xx not_active Application Discontinuation
- 2003-09-23 JP JP2004538994A patent/JP2006502195A/ja active Pending
- 2003-09-23 HR HR20050281A patent/HRP20050281A2/xx not_active Application Discontinuation
- 2003-09-23 DE DE60313344T patent/DE60313344T2/de not_active Expired - Lifetime
- 2003-09-23 MX MXPA05003161A patent/MXPA05003161A/es active IP Right Grant
- 2003-09-23 PT PT03798175T patent/PT1545534E/pt unknown
- 2003-09-23 WO PCT/EP2003/010578 patent/WO2004028542A1/en not_active Ceased
- 2003-09-23 ES ES03798175T patent/ES2285251T3/es not_active Expired - Lifetime
- 2003-09-23 US US10/528,914 patent/US20060128716A1/en not_active Abandoned
- 2003-09-23 EP EP03798175A patent/EP1545534B1/en not_active Expired - Lifetime
- 2003-09-23 CN CNB038227118A patent/CN100372535C/zh not_active Expired - Fee Related
- 2003-09-23 AT AT03798175T patent/ATE359789T1/de not_active IP Right Cessation
- 2003-09-23 BR BR0314647-2A patent/BR0314647A/pt not_active IP Right Cessation
- 2003-09-23 KR KR1020057004971A patent/KR20050074450A/ko not_active Ceased
-
2005
- 2005-03-16 ZA ZA200502212A patent/ZA200502212B/en unknown
- 2005-03-17 CR CR7754A patent/CR7754A/es not_active Application Discontinuation
- 2005-03-23 EC EC2005005700A patent/ECSP055700A/es unknown
- 2005-04-20 NO NO20051936A patent/NO20051936L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003299065B2 (en) | 2006-10-26 |
| JP2006502195A (ja) | 2006-01-19 |
| US20060128716A1 (en) | 2006-06-15 |
| ATE359789T1 (de) | 2007-05-15 |
| ECSP055700A (es) | 2005-08-11 |
| CN1684684A (zh) | 2005-10-19 |
| NO20051936L (no) | 2005-06-23 |
| RU2005112711A (ru) | 2006-02-27 |
| CR7754A (es) | 2005-12-02 |
| DE60313344D1 (de) | 2007-05-31 |
| PL374696A1 (en) | 2005-10-31 |
| WO2004028542A1 (en) | 2004-04-08 |
| ZA200502212B (en) | 2006-02-22 |
| CN100372535C (zh) | 2008-03-05 |
| ES2285251T3 (es) | 2007-11-16 |
| DE60313344T2 (de) | 2008-01-03 |
| HRP20050281A2 (en) | 2006-07-31 |
| BR0314647A (pt) | 2005-08-02 |
| EP1545534A1 (en) | 2005-06-29 |
| MXPA05003161A (es) | 2005-09-12 |
| EP1545534B1 (en) | 2007-04-18 |
| KR20050074450A (ko) | 2005-07-18 |
| RS20050228A (sr) | 2007-08-03 |
| AU2003299065A1 (en) | 2004-04-19 |
| RU2353364C2 (ru) | 2009-04-27 |
| PT1545534E (pt) | 2007-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1339458B1 (en) | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity | |
| NZ550174A (en) | Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof | |
| NZ533940A (en) | Combinations comprising epothilones and anti-metabolites | |
| AU2003299065B2 (en) | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes | |
| JP2020537689A (ja) | Ａ−ノル−５αアンドロスタン化合物を含む白血球増多製剤およびその使用 | |
| US20090233939A1 (en) | Treatment of amm | |
| KR20240056487A (ko) | 고형 종양을 치료하기 위한 약제학적 조성물 | |
| JP2006502195A5 (enExample) | ||
| AU2008203233B2 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| US20090239872A1 (en) | Treatment of mesothelioma | |
| US20060252763A1 (en) | Treatment of von hippel lindau disease | |
| ZA200306404B (en) | Combination comprising a signal transduction inhibitor and an epothilone derivative. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |